ClinicalTrials.gg
CompletedNCT03484780Updated May 20, 2020

VisONE Heart Failure Study: Pilot

An interventional study of VisONE ADS in Heart Failure With Reduced Ejection Fraction, HFrEF, sponsored by VisCardia Inc.. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-20.

Sponsored by VisCardia Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Heart Failure with a site in Ukraine — 3 open to participants now, 5 under way, 3 of them phase 3. Heart Failure · Ukraine.

Enrollment
21st of 21
15 · median 4,005
Started
2018
with 2 others
No phase
2 of 22
none open now
Registered
13th of 22
by date

Among the 22 studies in Heart Failure with a site in Ukraine, this one is the 21st largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 with no phase, and was the 13th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

3 of the 22 studies in Heart Failure with a site in Ukraine are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Heart Failure with a site in Ukraine, or all of them as a file.
02

Study summary

The VisONE HF pilot is a feasibility pilot for evaluating the benefits and risks of chronically delivering Asymptomatic Diaphragmatic Stimulation in medical refractory heart failure patients using the VisONE™ implantable system for 12 months.

Read the detailed description

This 12 month study is intended to validate the early benefits observed with Asymptomatic Diaphragmatic Stimulation (ADS) as a primary form of heart failure therapy with low rates and severity of adverse effects. Medical refractory symptomatic heart failure patients with reduced ejection fraction and no evidence of arrhythmias or ventricular dysynchrony will undergo laparoscopic implantation of the VisONE™ implantable system comprised of a pulse generator and two leads, programmed to deliver cardiac-gaited diaphragmatic stimulation pulses at asymptomatic outputs. Patients will be followed in pre-specified durations of 1,3,6 and 12-months using a series of evaluations of hemodynamic, echocardiographic, heart failure status, diaphragmatic function, implanted system data and standard safety measures including adverse events, for comparison with their baseline values. The results are intended to be used for designing a subsequent larger study for performing statistical power calculations.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction, HFrEF

Browse trials for

Keywords

  • Implantable Heart Failure Device Therapy
  • Asymptomatic Diaphragmatic Stimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • class II/III medical despite guideline indicated heart failure medications
  • Sinus rhythm with \<10% ectopy
  • EF ≤ 35%
  • NT-proBNP > 500 (250 if on loop diuretics)

Exclusion criteria

Exclusion Criteria

  • 6MHW >500 m or \< 200 m
  • Resting HR > 140 bpm
  • SBP \<80 mmHg or > 170 mmHg
  • Serum creatine > 2.5 mg/dL
  • Ventricular dyssynchrony by with QRS ≥ 140ms
  • Unstable angina, AMI, CABG, PTCA, CVA/, persistent AF, NSVT, sustained VT or VF, or DCCV within 3 months
  • Intermittent inotropic drug treatment
  • Existing pacemaker or indications for a pacemaker
  • Severe primary pulmonary disease including pulmonary arterial hypertension or severe , or other respiratory or lung diseases where FEV \< 50% or any condition with severe diaphragmatic dysfunction
  • Previous open laparotomy within 1 year or to laparoscopy, as determined by implanting physician
  • Known or active intra-abdominal infections, or known intra-abdominal pathology
  • Previous thoracic or abdominal organ transplant, transplant waiting list
  • Pregnancy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    VisONE ADS

    Patients implanted with a VisONE stimulator and leads for receiving continual Synchronized Diaphragmatic Stimulation

    Device: VisONE ADS

Interventions

  • DeviceVisONE ADS

    VisONE stimulator and leads for delivering continual Synchronized Diaphragmatic Stimulation

    Also known as: Synchronized Diaphragmatic Stimulation

06

What researchers measure

Primary outcomes

  1. Freedom from serious complications or adverse events during procedural recovery and acute therapy

    The following serious complications and adverse events will be analyzed for their rate and severity and compared to other implantable device systems * Excessive procedural or implanted system morbidity * Procedural or implanted system events resulting in unscheduled patient hospitalizations and surgical intervention * Incidences resulting in physician choice to permanently discontinue therapy

    Time frame: after 3 months of therapy

Secondary outcomes

  1. Freedom from complications or adverse events during chronic therapy

    The following adverse events will be analyzed for their rate and severity and compared to other implantable device systems * Procedural or implanted system events resulting in adverse patient symptoms * Degradation of respiratory function by spirometer measures associated with procedure or implanted system * Adverse events due to procedural or implanted system complications correctable by non re-operative means including system reprogramming or other readjustments

    Time frame: after 3 and 12 months of therapy

  2. Freedom from serious complications or adverse events during chronic therapy

    The following serious complications and adverse events will be analyzed for their rate and severity and compared to other implantable device systems * Excessive procedural or implanted system morbidity * Procedural or implanted system events resulting in unscheduled patient hospitalizations and surgical intervention * Incidences resulting in physician choice to permanently discontinue therapy

    Time frame: after 12 months of therapy

Other outcomes

  1. Clinical composite of heart failure and cardiac function

    The following outcomes will be analyzed determine the potential therapeutic impact on clinical heart failure management * NT Pro-BNP blood levels to assess heart failure status * Improvements to cardiac output, stroke volume or left ventricular filling * Improvements to left ventricular volumes or ejection fraction * Improvements to heart failure status, 6 minute hall walk, or assessment by heart failure questionnaire

    Time frame: after 0, 1, 3, 6 and 12 months of therapy

07

Study locations

3 sites
  • Tbilisi Heart and Vascular Clinic
    Tbilisi, 0159, Georgia
  • Kyiv City Heart Center
    Kiev, Ukraine
  • Amosov National Institute of Cardiovascular Surgery
    Kyiv, Ukraine
08

References and documents

Publications

  • Beeler R, Schoenenberger AW, Bauer P, Kobza R, Bergner M, Mueller X, Schlaepfer R, Zuber M, Erne S, Erne P. Improvement of cardiac function with device-based diaphragmatic stimulation in chronic heart failure patients: the randomized, open-label, crossover Epiphrenic II Pilot Trial. Eur J Heart Fail. 2014 Mar;16(3):342-9. doi: 10.1002/ejhf.20. Epub 2013 Dec 6. PubMed 24464736 ↗
  • Roos M, Kobza R, Jamshidi P, Bauer P, Resink T, Schlaepfer R, Stulz P, Zuber M, Erne P. Improved cardiac performance through pacing-induced diaphragmatic stimulation: a novel electrophysiological approach in heart failure management? Europace. 2009 Feb;11(2):191-9. doi: 10.1093/europace/eun377. PubMed 19168496 ↗
  • Jorbenadze A, Shaburishvili N, Mirro M, Zuber M, Erne P, Shaburishvili T. First-In-Human Visone Heart Failure Study: Asymptomatic Diaphragmatic Stimulation For Chronic Heart Failure With Reduced Ejection Fraction: Case Report. Journal of the American College of Cardiology. 2020;75(11) Supplement 1

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Dec 2019, 16 months.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's 16 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2018
First posted
Apr 2, 2018
StartActual
Jul 25, 2018
Primary completionActual
Dec 12, 2019
CompletionActual
Dec 12, 2019
Last update
May 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03484780
Lead sponsor
VisCardia Inc.
Collaborators
Clinical Accelerator Ltd., University of Glasgow, University Hospital, Zürich, Stiftung für Herz-und Kreislaufkrankheiten
Responsible party
Sponsor
First posted
Apr 2, 2018
Start date
Jul 25, 2018
Primary completion
Dec 12, 2019
Completion
Dec 12, 2019
Last update
May 20, 2020

Study contacts

Vitaly Demyanchuk, M.D. Ph.D.
principal investigator · Kyiv City Heart Center
Rudenko Vladimirovich, M.D.
principal investigator · Amosov National Institute of Cardiovascular Surgery
Tamaz Shaburishvil, M.D.
principal investigator · Tbilisi Heart and Vascular Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion